Availability, cost and affordability of essential medicines for chronic respiratory diseases in low-income and middle-income countries: a cross-sectional study.

Autor:	Stolbrink M; Clinical Sciences, Stellenbosch University, Stellenbosch, South Africa mstolbrink@doctors.org.uk.; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK., Ozoh OB; Department of Medicine, University of Lagos College of Medicine, Lagos, Nigeria.; Department of Medicine, Lagos University Teaching Hospital, Surulere, Nigeria., Halpin DMG; Department of Respirology, Royal Devon and Exeter Hospital, Exeter, UK., Nightingale R; Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK., Meghji J; Imperial College London, London, UK., Plum C; University Hospitals of Morecambe Bay NHS Trust, Kendal, UK., Allwood BW; Department of Pulmonology, Tygerberg Academic Hospital, Cape Town, South Africa.; Department of Pulmonology, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa., Jayasooriya S; Academic Unit of Primary Care, The University of Sheffield, Sheffield, UK., Mortimer K; Department of Medicine, University of Cambridge, Cambridge, UK.; Department of Medicine, University of KwaZulu-Natal College of Health Sciences, Durban, South Africa.; Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Jazyk:	angličtina
Zdroj:	Thorax [Thorax] 2024 Jun 14; Vol. 79 (7), pp. 676-679. Date of Electronic Publication: 2024 Jun 14.
DOI:	10.1136/thorax-2023-221349
Abstrakt:	Contemporary data on the availability, cost and affordability of essential medicines for chronic respiratory diseases (CRDs) across low-income and middle-income countries (LMICs) are missing, despite most people with CRDs living in LMICs. Cross-sectional data for seven CRD medicines in pharmacies, healthcare facilities and central medicine stores were collected from 60 LMICs in 2022-2023. Medicines for symptomatic relief were widely available and affordable, while preventative treatments varied widely in cost, were less available and largely unaffordable. There is an urgent need to address these issues if the Sustainable Development Goal 3 is to be achieved for people with asthma by 2030. Competing Interests: Competing interests: KM reports advisory board fees from AstraZeneca and GlaxoSmithKline. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu